Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats

A. Tamás, Andrea Zsombok, O. Farkas, D. Reglodi, J. Pál, A. Büki, I. Lengvári, John T. Povlishock, T. Dóczi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system. Numerous studies have shown its neuroprotective effects both in vitro and in vivo. Previously, it has been demonstrated that PACAP reduces brain damage in rat models of global and focal cerebral ischemia. Based on the protective effects of PACAP in cerebral ischemia and the presence of common pathogenic mechanisms in cerebral ischemia and traumatic brain injury (TBI), the aim of the present study was to investigate the possible protective effect of PACAP administered 30 min or 1 h postinjury in a rat model of diffuse axonal injury. Adult Wistar male rats were subjected to impact acceleration, and PACAP was administered intracerebroventricularly 30 min (n = 4), and 1 h after the injury (n = 5). Control animals received the same volume of vehicle at both time-points (n = 5). Two hours after the injury, brains were processed for immunhistochemical localization of damaged axonal profiles displaying either β-amyloid precursor protein (β-APP) or RMO-14 immunoreactivity, both considered markers of specific features of traumatic axonal injury. Our results show that treatment with PACAP (100 μg) 30 min or 1 h after the induction of TBI resulted in a significant reduction of the density of β-APP-immunopositive axon profiles in the corticospinal tract (CSpT). There was no significant difference between the density of β-APP-immunopositive axons in the medial longitudinal fascicle (MLF). PACAP treatment did not result in significantly different number of RMO-14-immunopositive axonal profiles in either brain areas 2 hours post-injury compared to normal animals. While the results of this study highlighted the complexity of the pathogenesis and manifestation of diffuse axonal injury, they also indicate that PACAP should be considered a potential therapeutic agent in TBI.

Original languageEnglish
Pages (from-to)686-695
Number of pages10
JournalJournal of Neurotrauma
Volume23
Issue number5
Publication statusPublished - May 2006

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Wounds and Injuries
Brain Ischemia
Diffuse Axonal Injury
Axons
Pyramidal Tracts
Amyloid beta-Protein Precursor
Brain
Neuroprotective Agents
Brain Injuries
Nervous System
Wistar Rats

Keywords

  • β-amyloid precursor protein
  • Corticospinal tract
  • Neuroprotection
  • PACAP
  • Traumatic brain injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

@article{554ba8aa498d4aa28c2d0dc4d547b692,
title = "Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats",
abstract = "Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system. Numerous studies have shown its neuroprotective effects both in vitro and in vivo. Previously, it has been demonstrated that PACAP reduces brain damage in rat models of global and focal cerebral ischemia. Based on the protective effects of PACAP in cerebral ischemia and the presence of common pathogenic mechanisms in cerebral ischemia and traumatic brain injury (TBI), the aim of the present study was to investigate the possible protective effect of PACAP administered 30 min or 1 h postinjury in a rat model of diffuse axonal injury. Adult Wistar male rats were subjected to impact acceleration, and PACAP was administered intracerebroventricularly 30 min (n = 4), and 1 h after the injury (n = 5). Control animals received the same volume of vehicle at both time-points (n = 5). Two hours after the injury, brains were processed for immunhistochemical localization of damaged axonal profiles displaying either β-amyloid precursor protein (β-APP) or RMO-14 immunoreactivity, both considered markers of specific features of traumatic axonal injury. Our results show that treatment with PACAP (100 μg) 30 min or 1 h after the induction of TBI resulted in a significant reduction of the density of β-APP-immunopositive axon profiles in the corticospinal tract (CSpT). There was no significant difference between the density of β-APP-immunopositive axons in the medial longitudinal fascicle (MLF). PACAP treatment did not result in significantly different number of RMO-14-immunopositive axonal profiles in either brain areas 2 hours post-injury compared to normal animals. While the results of this study highlighted the complexity of the pathogenesis and manifestation of diffuse axonal injury, they also indicate that PACAP should be considered a potential therapeutic agent in TBI.",
keywords = "β-amyloid precursor protein, Corticospinal tract, Neuroprotection, PACAP, Traumatic brain injury",
author = "A. Tam{\'a}s and Andrea Zsombok and O. Farkas and D. Reglodi and J. P{\'a}l and A. B{\"u}ki and I. Lengv{\'a}ri and Povlishock, {John T.} and T. D{\'o}czi",
year = "2006",
month = "5",
language = "English",
volume = "23",
pages = "686--695",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats

AU - Tamás, A.

AU - Zsombok, Andrea

AU - Farkas, O.

AU - Reglodi, D.

AU - Pál, J.

AU - Büki, A.

AU - Lengvári, I.

AU - Povlishock, John T.

AU - Dóczi, T.

PY - 2006/5

Y1 - 2006/5

N2 - Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system. Numerous studies have shown its neuroprotective effects both in vitro and in vivo. Previously, it has been demonstrated that PACAP reduces brain damage in rat models of global and focal cerebral ischemia. Based on the protective effects of PACAP in cerebral ischemia and the presence of common pathogenic mechanisms in cerebral ischemia and traumatic brain injury (TBI), the aim of the present study was to investigate the possible protective effect of PACAP administered 30 min or 1 h postinjury in a rat model of diffuse axonal injury. Adult Wistar male rats were subjected to impact acceleration, and PACAP was administered intracerebroventricularly 30 min (n = 4), and 1 h after the injury (n = 5). Control animals received the same volume of vehicle at both time-points (n = 5). Two hours after the injury, brains were processed for immunhistochemical localization of damaged axonal profiles displaying either β-amyloid precursor protein (β-APP) or RMO-14 immunoreactivity, both considered markers of specific features of traumatic axonal injury. Our results show that treatment with PACAP (100 μg) 30 min or 1 h after the induction of TBI resulted in a significant reduction of the density of β-APP-immunopositive axon profiles in the corticospinal tract (CSpT). There was no significant difference between the density of β-APP-immunopositive axons in the medial longitudinal fascicle (MLF). PACAP treatment did not result in significantly different number of RMO-14-immunopositive axonal profiles in either brain areas 2 hours post-injury compared to normal animals. While the results of this study highlighted the complexity of the pathogenesis and manifestation of diffuse axonal injury, they also indicate that PACAP should be considered a potential therapeutic agent in TBI.

AB - Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system. Numerous studies have shown its neuroprotective effects both in vitro and in vivo. Previously, it has been demonstrated that PACAP reduces brain damage in rat models of global and focal cerebral ischemia. Based on the protective effects of PACAP in cerebral ischemia and the presence of common pathogenic mechanisms in cerebral ischemia and traumatic brain injury (TBI), the aim of the present study was to investigate the possible protective effect of PACAP administered 30 min or 1 h postinjury in a rat model of diffuse axonal injury. Adult Wistar male rats were subjected to impact acceleration, and PACAP was administered intracerebroventricularly 30 min (n = 4), and 1 h after the injury (n = 5). Control animals received the same volume of vehicle at both time-points (n = 5). Two hours after the injury, brains were processed for immunhistochemical localization of damaged axonal profiles displaying either β-amyloid precursor protein (β-APP) or RMO-14 immunoreactivity, both considered markers of specific features of traumatic axonal injury. Our results show that treatment with PACAP (100 μg) 30 min or 1 h after the induction of TBI resulted in a significant reduction of the density of β-APP-immunopositive axon profiles in the corticospinal tract (CSpT). There was no significant difference between the density of β-APP-immunopositive axons in the medial longitudinal fascicle (MLF). PACAP treatment did not result in significantly different number of RMO-14-immunopositive axonal profiles in either brain areas 2 hours post-injury compared to normal animals. While the results of this study highlighted the complexity of the pathogenesis and manifestation of diffuse axonal injury, they also indicate that PACAP should be considered a potential therapeutic agent in TBI.

KW - β-amyloid precursor protein

KW - Corticospinal tract

KW - Neuroprotection

KW - PACAP

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=33646587645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646587645&partnerID=8YFLogxK

M3 - Article

C2 - 16689670

AN - SCOPUS:33646587645

VL - 23

SP - 686

EP - 695

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 5

ER -